New RACGP-approved Tutorial Focuses on Two New Insulins
A new tutorial titled ‘New Insulins’ have been added to the Diabetes Academy: What’s New in Diabetes online course. This new material had recently been approved by the Royal Australian College of General Practitioners and is ready for release today.
The author of this tutorial is Associate Professor Shane Hamblin MBBS (Hons) FRACP, the Head of Endocrinology and Diabetes at Western Health and Consultant Endocrinologist at Alfred Health. The course is directed by Associate Professor Elif Ekinci MBBS FRACP PhD, the Director of Diabetes of Western Health.
The new tutorial focuses on the new insulins that are now available on the Pharmaceutical Benefits Scheme (PBS): Ryzodeg 70/30 (Insulin degludec and Insulin aspart) and Toujeo (Insulin glargine 300 units/mL).
Despite the availability of new oral agents for type 2 diabetes and the development of GLP-1 analogues, insulin will still be needed for many people, given that endogenous insulin output falls significantly over time as part of the natural history of type 2 diabetes. Additionally, people with type 1 diabetes for various reasons may not use basal-bolus insulin (quick acting, three times a day, and long acting, once or twice a day) but may prefer fewer injections, which may be possible using pre-mixed insulin.
Learners can gain information about the components of Ryzodeg 70/30 and Toujeo, how to determine the time course of action with each insulin, learn about when these insulins can be used appropriately, and find out about the common adverse effects and safety precautions.
The tutorial also contains interactive segments, reflective questions and quizzes, and 5 exam questions.